MOCS2-DT: A Potential Drug Target and Biomarker for Alzheimer's Disease

Target Name: MOCS2-DT

NCBI ID: G257396

MOCS2-DT

Other Name(s): MOCS2-DT variant 1 | MOCS2 divergent transcript, transcript variant 1 | MOCS2 divergent transcript

MOCS2-DT: A Potential Drug Target and Biomarker for Alzheimer's Disease

MOCS2-DT, or MOCS2-Dietrich's-Trans, is a protein that is expressed in the brain and is involved in the development and progression of several neurological disorders, including Alzheimer's disease. The MOCS2 gene has been identified as a potential drug target for the treatment of these disorders.

MOCS2 is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells. The protein is composed of 218 amino acid residues and has a calculated molecular weight of 23.9 kDa. It is expressed in the brain and is involved in the development and progression of several neurological disorders, including Alzheimer's disease.

One of the most promising aspects of MOCS2 is its potential as a drug target. The MOCS2 gene has been shown to be involved in the development and progression of several neurological disorders, including Alzheimer's disease. Studies have shown that MOCS2 is overexpressed in the brains of individuals with Alzheimer's disease and that inhibition of the MOCS2 gene has been shown to protect against the development of these disorders.

In addition to its potential as a drug target, MOCS2 is also a potential biomarker for the diagnosis and progression of Alzheimer's disease. The protein is expressed in the brain and has been shown to be involved in the development and progression of several neurological disorders, including Alzheimer's disease. Therefore, MOCS2 may be a useful biomarker for the diagnosis and progression of these disorders.

The MOCS2 gene has also been shown to be involved in the development and progression of other neurological disorders, including Parkinson's disease and multiple sclerosis. Therefore, further research is needed to fully understand the role of MOCS2 in these disorders.

In conclusion, MOCS2-DT is a protein that is expressed in the brain and is involved in the development and progression of several neurological disorders, including Alzheimer's disease. The MOCS2 gene has been shown to be involved in the development and progression of these disorders, and therefore MOCS2-DT may be a potential drug target and biomarker for the treatment of these disorders. Further research is needed to fully understand the role of MOCS2 in these disorders.

Protein Name: MOCS2 Divergent Transcript

The "MOCS2-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MOCS2-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets